Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in … – Yahoo Finance
Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in …Yahoo FinanceKite Pharma, Inc., (KITE) today announced two plenary presentations of positive data from the primary analysis of ZUMA-1 f… Continue reading
